The introduction of biolologic therapy (infliximab, adalimumab) has led to a deep transformation in the management of inflammatory bowel disease (Crohn's disease and ulcerative colitis). Despite their proven efficacy, open issues still remain about their long term safety profile and the optimization of their use; particularly as far as the personalization of the therapy is concerned.
|Translated title of the contribution||Biologic therapy in inflammatory bowel disease|
|Number of pages||5|
|Journal||Giornale Italiano di Endoscopia Digestiva|
|Publication status||Published - Sep 2013|
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging